What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LM-108 combined with Toripalimab administered intravenously on Day 1 every 3 weeks”In the company’s words, NCT07362186 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor (3 trials), Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Advanced Pancreatic Cancer
- Main trialPhase 3
- “This is a phase III, Multicenter, Randomized study, evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.”In the company’s words, NCT07362186 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up3
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 26 Jan 2028Phase 2 trial completes · ClinicalTrials.gov
- 17 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 17 Aug 2028 | LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma | |
| Phase 2Not yet recruiting | 26 Jan 2028 | A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours | |
| Phase 1/2Recruiting | Mar 2026 | Clinical Studies for the Treatment of Advanced Solid Tumors | |
| Phase 1/2Active, not recruiting | 31 Oct 2026 | A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | |
| Phase 1/2Recruiting | Dec 2027 | Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C | |
| Phase 1/2Terminated | 6 Oct 2023 | Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | |
| Phase 1/2Completed | 31 Dec 2024 | Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026